Evidence map›Paper›PMID 42086351›Full record

ArticleThe Canadian journal of urology2026

Overweight status predicts improved overall survival after radical nephroureterectomy for upper tract urothelial carcinoma.

Shu-Yu Wu, Ching-Chia Li, Wen-Jeng Wu, Kuan-Hua Huang, Chien-Liang Liu, Shian-Shiang Wang, Jian-Ri Li, Han-Yu Weng, Ta-Yao Tai, Pi-Che Chen and 21 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in The Canadian journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Shu-Yu WuDepartment of Urology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, 231, Taiwan.
Ching-Chia LiDepartment of Urology, Kaohsiung Medical University Hospital, Kaohsiung, 807, Taiwan.
Wen-Jeng WuDepartment of Urology, Kaohsiung Medical University Hospital, Kaohsiung, 807, Taiwan.
Kuan-Hua HuangDivision of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, 710, Taiwan.
Chien-Liang LiuDivision of Urology, Division of Urological Oncology, Department of Surgery, Chi-Mei Medical Center, Tainan, 710, Taiwan.
Shian-Shiang WangDivision of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, 407, Taiwan.
Jian-Ri LiDivision of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, 407, Taiwan.
Han-Yu WengDepartment of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704, Taiwan.
Ta-Yao TaiDepartment of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704, Taiwan.
Pi-Che ChenDepartment of Urology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, 600, Taiwan.
Ian-Seng CheongDepartment of Urology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, 600, Taiwan.
Chung-You TsaiDivision of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan.
Pai-Yu ChengDivision of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan.
Jian-Hua HongInstitute of Biomedical Engineering, National Taiwan University, Taipei, 106, Taiwan.
Chung-Hsin ChenDepartment of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.
Jen-Shu TsengDepartment of Urology, MacKay Memorial Hospital, Taipei, 104, Taiwan.
Wun-Rong LinDepartment of Urology, MacKay Memorial Hospital, Taipei, 104, Taiwan.
Yuan-Hong JiangDepartment of Urology, School of Medicine, Tzu Chi University, Hualien, 970, Taiwan.
Yu-Khun LeeDepartment of Urology, School of Medicine, Tzu Chi University, Hualien, 970, Taiwan.
Po-Hung LinDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, 333, Taiwan.
See-Tong PangDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, 333, Taiwan.
Yung-Tai ChenDepartment of Urology, Taiwan Adventist Hospital, Taipei, 105, Taiwan.
Wei-Chieh ChenDepartment of Urology, Taipei Medical University Hospital, Taipei Medical University, Taipei, 110, Taiwan.
Chia-Chang WuDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, 235, Taiwan.
Thomas Y HsuehDivision of Urology, Department of Surgery, Taipei City Hospital, Taipei, 103, Taiwan.
Hsu-Che HuangDivision of Urology, Department of Surgery, Cardinal Tien Hospital, New Taipei City, 231, Taiwan.
Wei-Yu LinDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chiayi, 613, Taiwan.
Chia-Cheng YuDivision of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, 813, Taiwan.
Jen-Kai FangDepartment of Urology, China Medical University Hospital, Taichung, 404, Taiwan.
Chih-Chin YuDepartment of Urology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, 231, Taiwan.
Yao-Chou TsaiDepartment of Urology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, 231, Taiwan.

Funding

Buddhist Tzu Chi Medical Foundation TCMF-JCT-113-09Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation TCRD-TPE-112-12Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation TCRD-TPE-113-32
6 · The paper itself

Abstract

introductionUpper urinary tract urothelial carcinoma (UTUC) is a rare malignancy, particularly in the ureter, and is associated with high rates of recurrence and metastasis. Although body mass index (BMI) has been associated with prognosis in multiple cancer types, its role as a predictive factor in UTUC is still debated. This study aimed to investigate how BMI influences survival outcomes in patients with UTUC treated with radical nephroureterectomy (RNU).

methodsThis multi-center retrospective analysis by the Taiwan UTUC Collaboration Group involved 2503 patients who underwent treatment across 19 hospitals from 1988 to 2022. Patients were categorized into normal (18.5 ≤ BMI < 24), overweight (24 ≤ BMI < 27), and obese (BMI ≥ 27) groups. Demographic, clinical, and pathological data were analyzed. Overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and intravesical recurrence-free survival (IVRFS) were assessed using Kaplan-Meier analysis and Cox proportional hazards models.

resultsThe median follow-up period was 44.2 months. In multivariable analysis, overweight patients demonstrated significantly better OS compared with normal-weight patients (p = 0.033), and the obesity group showed a favorable, though not statistically significant, trend toward better OS. However, BMI was not an independent predictor of CSS, DFS, or IVRFS. Independent predictors of worse outcomes included older age, end-stage renal disease, ureteral tumor location, tumor size ≥3 cm, and high-grade urothelial carcinoma. Tumor stage and grade were comparable across BMI groups.

conclusionsOverweight status was associated with better OS in patients with UTUC treated with RNU, while BMI had no significant impact on CSS, DFS, or IVRFS. These findings suggest a potential protective effect of higher BMI on OS, warranting further investigation in prospective studies. However, BMI alone should not guide clinical decisions and may instead reflect broader patient health characteristics.

Indexed as

Carcinoma, Transitional CellKidney NeoplasmsNephroureterectomyOverweightUreteral NeoplasmsAgedBody Mass IndexFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateTaiwanbody mass indexoncological outcomesradical nephroureterectomyupper urinary tract urothelial carcinomaUrothelial cancer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.